Activated protein C resistance : Role in venous and arterial thrombosis;La résistance à l'action de la protéine C activée : R̂le dans la thrombose veineuse et artérielle

Archives des Maladies du Coeur et des Vaisseaux

Volumn 89, Issue 6, 1996, Pages 741-745

  Emmerich, J ^a   Alhenc Gelas, M ^b   Aiach, M ^b   Fiessinger, J N ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C; BLOOD CLOTTING FACTOR 5;

ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; MUTATION; PATHOGENESIS; REVIEW; THROMBOPHILIA; BLOOD CLOTTING DISORDER; DRUG RESISTANCE; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; POINT MUTATION; THROMBOSIS;

BLOOD COAGULATION DISORDERS; DRUG RESISTANCE; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; PROTEIN C; THROMBOSIS;

EID: 0029894972     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Dahlbäck B, Corlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993 ; 90: 1004-8.
2. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994 ; 91 : 1396-400.
3. Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994 ; 83 : 3120-5.
4. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 1994 ; 269 : 18735-8.
5. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994 ; 369 : 64-7.
6. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance : molecular mechanisms based on studies using purified Gin 506-factor V. Blood 1995 ; 85 : 3405-11.
7. Alhenc-Gelas M, Gandrille S, Aubry ML et al. Unexplained thrombosis and factor Leiden mutation. Lancet 1994 ; 344 : 555.
8. Griffin JH, Evatt B, Wldeman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993 ; 82 : 1989-93.
9. Koster T, Rosendaal FR, De Ronde H, Briët E, Vanden Broucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C : Leiden thrombophilia study. Lancet 1993 ; 342 : 1503-6.
10. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994 ; 330 : 517-22.
11. Legnani C, Plareti G, Biagi P, Coccheri S. Activated protein C resistance in deep vein thrombosis. Lancet 1994 ; 343 : 541-2.
12. Cadroy Y, Sié P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994 ; 83 : 2008-9.
13. Trossaërt M, Canard J, Horellou MH, Samaha M, Elalamy I, Samama MM. Résistance àla protéine C activée dans les accidents thromo-emboliques veineux : fréquence et manifestations cliniques. Presse Med 1995 ; 24 : 209-12.
14. Gallus AS, Hirsh J, Gent M. Relevance of preoperative and postoperative blood tests to post-operative leg-vein thrombosis. Lancet 1973 ; 2 : 805-9.
15. Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995; 74 : 139-48.
16. Emmerich J, Poirier O, Evans A et al. Myocardial infarction, Arg 506 to Glan factor V mutation, and activated protein C resistance. Lancet 1995 ; 345 : 321.
17. Greengard J, Eichinger S, Griffin JH, Bauer K. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg/Gln mutation in the gene for factor V. N Engl J Med 1994 ; 331 : 1559-62.
18. Vondenbrouchke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 ; 344 : 1453-7.
19. Levoir D, Emmerich J, Alhenc-Gelas M et al. Portal vein thrombosis and factor V Arg 506 to Gln mutation. Thromb Haemost 1995; 73: 550-1.
20. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993 ; 72 : 477-80.
21. Gandrille S, Greengard JS, Alhenc-Gelas M et al. Incidence of activated protein resistance caused by the Arg 506 Gin mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995 ; 86 : 219-24.
22. Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994; 5: 51-7.
23. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995 ; 332: 912-7.
24. März W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Wilt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995 ; 345 : 526-7.
25. Van Bockwmeer FM. Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nature Med 1995; 1 : 185.
26. Kontula K, Ylikorkala A, Miettinen H et al. Arg 506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995 ; 73 : 558-60.
27. Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction. Lancet 1994 ; 344 : 1709-10.
28. Eritsland J, Gjonnes G, Sandset PM et al. Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res 1995 ; 79 : 223-6.
29. Forsyth PD, Dolan G. Activted protein C resistance in cases of cerebral infarction. Lancet 1995 ; 345 : 795.
30. Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 1994; 72: 647.
31. Page Y, Descoussus H, Comtet C et al. Indications actuelles des interruptions de la veine cave inférieure. Arch Mal Coeur 1991 ; 84 : 1747-54.